In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company’s mission, and the challenges ahead.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal